MCA2_PLAF7
ID MCA2_PLAF7 Reviewed; 2020 AA.
AC Q8IL84;
DT 07-OCT-2020, integrated into UniProtKB/Swiss-Prot.
DT 22-SEP-2009, sequence version 2.
DT 25-MAY-2022, entry version 95.
DE RecName: Full=Metacaspase-2 {ECO:0000303|PubMed:29317266};
DE EC=3.4.22.- {ECO:0000269|PubMed:29317266, ECO:0000269|PubMed:32202613};
DE AltName: Full=PfMCA2 {ECO:0000303|PubMed:29317266};
GN Name=MCA2 {ECO:0000303|PubMed:29317266};
GN ORFNames=PF3D7_1438400 {ECO:0000312|EMBL:CZU00080.1};
OS Plasmodium falciparum (isolate 3D7).
OC Eukaryota; Sar; Alveolata; Apicomplexa; Aconoidasida; Haemosporida;
OC Plasmodiidae; Plasmodium; Plasmodium (Laverania).
OX NCBI_TaxID=36329 {ECO:0000312|Proteomes:UP000001450};
RN [1] {ECO:0000312|Proteomes:UP000001450}
RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC STRAIN=3D7 {ECO:0000312|Proteomes:UP000001450};
RX PubMed=12368864; DOI=10.1038/nature01097;
RA Gardner M.J., Hall N., Fung E., White O., Berriman M., Hyman R.W.,
RA Carlton J.M., Pain A., Nelson K.E., Bowman S., Paulsen I.T., James K.D.,
RA Eisen J.A., Rutherford K.M., Salzberg S.L., Craig A., Kyes S., Chan M.-S.,
RA Nene V., Shallom S.J., Suh B., Peterson J., Angiuoli S., Pertea M.,
RA Allen J., Selengut J., Haft D., Mather M.W., Vaidya A.B., Martin D.M.A.,
RA Fairlamb A.H., Fraunholz M.J., Roos D.S., Ralph S.A., McFadden G.I.,
RA Cummings L.M., Subramanian G.M., Mungall C., Venter J.C., Carucci D.J.,
RA Hoffman S.L., Newbold C., Davis R.W., Fraser C.M., Barrell B.G.;
RT "Genome sequence of the human malaria parasite Plasmodium falciparum.";
RL Nature 419:498-511(2002).
RN [2] {ECO:0000305}
RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, BIOPHYSICOCHEMICAL
RP PROPERTIES, SUBCELLULAR LOCATION, DEVELOPMENTAL STAGE, AND INDUCTION.
RX PubMed=29317266; DOI=10.1016/j.molbiopara.2018.01.001;
RA Vandana X., Singh A.P., Singh J., Sharma R., Akhter M., Mishra P.K.,
RA Saxena A.K., Dixit R., Rathi B., Katyal A., Pandey K.C.;
RT "Biochemical characterization of unusual cysteine protease of P.
RT falciparum, metacaspase-2 (MCA-2).";
RL Mol. Biochem. Parasitol. 220:28-41(2018).
RN [3] {ECO:0000305}
RP FUNCTION, CATALYTIC ACTIVITY, AND DEVELOPMENTAL STAGE.
RX PubMed=32202613; DOI=10.1042/bcj20200050;
RA Vandana X., Shankar S., Prasad K.M., Kashif M., Kalia I., Rai R.,
RA Singh A.P., Pandey K.C.;
RT "A nonpeptidyl molecule modulates apoptosis-like cell death by inhibiting
RT P. falciparum metacaspase-2.";
RL Biochem. J. 477:1323-1344(2020).
CC -!- FUNCTION: Protease that cleaves specifically after arginine or lysine
CC residues (PubMed:29317266, PubMed:32202613). May play a role in
CC parasite growth and/or development (PubMed:29317266, PubMed:32202613).
CC {ECO:0000269|PubMed:29317266, ECO:0000269|PubMed:32202613}.
CC -!- ACTIVITY REGULATION: Ca(2+) does not appear to affect catalytic
CC activity. {ECO:0000269|PubMed:29317266}.
CC -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC pH dependence:
CC Optimum pH is 7.5. {ECO:0000269|PubMed:29317266};
CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:29317266}.
CC -!- DEVELOPMENTAL STAGE: Expressed during the parasite blood stage,
CC specifically in schizonts, and gametocytes (at protein level).
CC {ECO:0000269|PubMed:29317266, ECO:0000269|PubMed:32202613}.
CC -!- INDUCTION: Up-regulated by oxidative stress.
CC {ECO:0000269|PubMed:29317266}.
CC -!- SIMILARITY: Belongs to the peptidase C14B family. {ECO:0000305}.
CC -!- CAUTION: In contrast to other metacaspases of the peptidase C14B
CC family, the catalytic histidine and cysteine residues do not appear to
CC be conserved. {ECO:0000305}.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; LN999946; CZU00080.1; -; Genomic_DNA.
DR RefSeq; XP_001348537.2; XM_001348501.2.
DR AlphaFoldDB; Q8IL84; -.
DR SMR; Q8IL84; -.
DR IntAct; Q8IL84; 1.
DR STRING; 5833.PF14_0363; -.
DR PRIDE; Q8IL84; -.
DR EnsemblProtists; CZU00080; CZU00080; PF3D7_1438400.
DR GeneID; 811945; -.
DR KEGG; pfa:PF3D7_1438400; -.
DR VEuPathDB; PlasmoDB:PF3D7_1438400; -.
DR HOGENOM; CLU_233595_0_0_1; -.
DR InParanoid; Q8IL84; -.
DR OMA; CGYSIKI; -.
DR PhylomeDB; Q8IL84; -.
DR Proteomes; UP000001450; Chromosome 14.
DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR GO; GO:0008233; F:peptidase activity; IDA:UniProtKB.
DR GO; GO:0006508; P:proteolysis; IDA:UniProtKB.
PE 1: Evidence at protein level;
KW Cytoplasm; Hydrolase; Protease; Reference proteome.
FT CHAIN 1..2020
FT /note="Metacaspase-2"
FT /id="PRO_0000451188"
FT REGION 51..78
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 573..614
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ SEQUENCE 2020 AA; 237831 MW; 58B6E56CF3408C8C CRC64;
MNSMNTYSPL YSSYENINIY KKNRKFEEDN YETSTANISC DSKGRILVKE SENDRNESIQ
KKQMLSSMDN RKTNKSEKHN ISSYYKMRKK ASNHLKDKEK LNNNIIYAKN PHANRYDKYY
SLNMNIMNNM NNMNNMNNVN NMNNVNNMNN VNNMNNMNNV NNMNNMNNVN NMNNVKSMYN
NNNNSNVYYR ISRQNINGKE RLLNRYNIMR PQRSADMLIR NYLYNDLPYE INQQNLNKNI
NDNNAGSFDN LNKTVFENYN KNILDEYNRN IMQYYNSNLK NYRNSSFDNI YTRYNNNNNN
NNVYSNNNVY SNNNIYNNNN NNDNINNSFQ FSKQEGLMKI YSNNNRNMND YVVKTSNITR
AADNTCAQEQ INIPTYNKTV LLKSSPNTEN TFNKTLSNIL KEQPKRSSMF SFNSSDFFKD
FGKLRKNFVG KKKNKINKDI VINGNIFNNK IIDNNTSNAK SEGNSTLHKI YNFIFPSSVK
KLQKKKQKLQ VIEDKEKNSN RAVVMPLKNK IIYINDANIT NDKFKHSFEN YNYHQTNIPF
VSVTNYMNKD STKNVRSFSS FDVKERISPR VIRNGNINNN KNNNINNNNN NINNNNNNIN
NNNNNINNNN NINNNNNINN NNNINNNNNI NNNNINNINN INNDFVNDSN INKTVNIHNN
NNNLNNYSNT MKSVAKNTQK LSAQKNSLVN DKHHTYHEKL ITNIYQFTGG QSQKSCNIKN
QNVKEEKINN TQISYINNTA YNDYTNLPNV ETYVLSEKSN NLENKEDNNI NEKFKNDNNV
DKKNNDENNI IKHNVNQNNN EVIVMNNQTE EQINDNKFIK PLNNITGIDP KKKNIYNTVM
HINDKMDLNK HDYNYNYNNI IPHNYINSSD KMTNNSLHIN KKADDIFQNM ISNNDTNVPC
VYVNKYINNI FQNNNPSNVT NYINTINMNK APITIDENSN KLDNNINYEN VTKNMIYNNY
TNNNVLYITK EKSDNKLNNS TNHLNDLKNN YYVINPSLLY IHNNNNNIEW NKQYTNNFSK
PNFLDKFFYE KKVESIQPHH LNQYYYNNQN VKYNPSHINI LENKYVNQFT NQNENSLYNF
TTHHNNIKNN NIDNILLLDK AIRNQSIYYN NNKGDDETKS AEHTTNPSIN LLKNNYEDKN
KSNYVHSIVS ITDKDNSIYA KNKYAEVVTK NNEKREDAIH KKDEQYIFNN NDNNNDNIHN
NNIHNNIHNN IHNNIHNNIH NNIHNNIHNN IHNNIHNNIH NNIHNNIDVS SRENFFQHDI
QNTNQINNKT ILDITQNEKP NATNEKCLDI NNKEKKKKKI KSVHYDMDEI LSLKCKVYDE
LDTCLKCINN LTKNKKLYEQ LKKYKHKLDK DTKTKKLYDE CTSEKTGSYY TMKDSYISSL
LCNEYKLNHI LNKSNNKVSD DKHILSYNHH HNKNNNINDI NNIKHISKFV NKDNEKTLNN
INILNHNNKD PNSGVFLPSD NTESVIYNMN RNRKLCDNNF NVSKHVLYKD SKGTDSTRTN
FYDDYSMSYV KSNVDNVEKK EKIKNNINIS DKYFLSETDS PYIGKKKALM ITLNYNGLLE
GCVNDTVDMC DHLMQRFGFN DFILLNDCNL CYRNFVTQKA NKKNILSNLH NFIVNSNNGD
ILFFYFCGYS IKLIDSKFTE NYNFALLPQD HSKNNYIYSN EIFNIIKKLQ GGKQLCIIFD
TTYTSYFVPV PTSITYNKNM NTTEIYKYNN FSSNQKYLKS LKTFGKIRDR NVDSIFVENI
KKPLLYEIYK KENDTNTNDK IILVPSIFFF SPDCNDRNDF EFSIKNKVRG LLTYCLGKAI
ELLKNDFSYH DLFVAASQIL IDIKKEYNLK YVKFKLSFLN EYSPDDIKFL SHESLFLKKK
LQLDEPLWKP SLKLNNLNQY IQDICNMDER KMLKSSKKKC LLIFIKDIKF YTYKNIDTKN
EYFVSCFIKN KNVNILCVRR NNTKEQRIVQ DKIFFLEYIT LNVTHMENAN IYVELFKKKK
KNYFVARSIF NIRNVNGKFS LSDEKKNIIG IIDLNIKCVS
